Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of BILR 355 BS and Kaletra in Healthy Volunteers
NCT02256826Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2005
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of BILR 355 in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state (0-12h) and Maximum measured concentration at steady state at 96 hours. Started Apr 2005; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02256826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256826.